Loading...
•
Dec 31, 2021
Elanco Q4 2021 Earnings Report
Elanco reported a decrease in revenue but an increase in gross profit and adjusted EPS for Q4 2021.
Key Takeaways
Elanco Animal Health reported a decrease in revenue by 2% to $1,113 million in Q4 2021, but an increase in gross profit to $601 million. Adjusted EPS increased by 75% to $0.21 per share and adjusted EBITDA increased by 20% to $212 million.
Revenue was $1,113 million, a decrease of 2% compared to Q4 2020.
Gross profit was $601 million, or 54.0% of revenue, compared to $544 million, or 47.7% for Q4 2020.
Adjusted EPS in the quarter was $0.21 per share, an increase of 75% as compared to Q4 2020.
Adjusted EBITDA was $212 million, an increase of 20% compared to Q4 2020.
Forward Guidance
Elanco anticipates revenue between $4,745 million and $4,800 million for the full year 2022, with a headwind of approximately $95 million from the unfavorable impact for foreign exchange rates. The company expects revenue between $1,200 million and $1,230 million for the first quarter of 2022.
Positive Outlook
- Growth is expected to be driven by newly launched innovation products
- Increased price across the portfolio
- Growth in key focus brands
Challenges Ahead
- Lower revenue as a result of competitive pressure in the U.S. pet health parasiticides market
- Headwinds in the China swine business
- The reduction of contract manufacturing revenue
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...